Literature DB >> 23772620

Dendritic cell dysregulation during HIV-1 infection.

Elizabeth Miller1, Nina Bhardwaj.   

Abstract

Dendritic cells (DCs) are a diverse subset of innate immune cells that are key regulators of the host response to human immunodeficiency virus-1 (HIV-1) infection. HIV-1 directly and indirectly modulates DC function to hinder the formation of effective antiviral immunity and fuel immune activation. This review focuses upon the differential dysregulation of myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) at various stages of HIV-1 infection providing insights into pathogenesis. HIV-1 evades innate immune sensing by mDCs resulting in suboptimal maturation, lending to poor generation of antiviral adaptive responses and contributing to T-regulatory cell (Treg) development. Dependent upon the stage of HIV-1 infection, mDC function is altered in response to Toll-like receptor ligands, which further hinders adaptive immunity and limits feasibility of therapeutic vaccine strategies. pDC interactions with HIV-1 are pleotropic, modulating immune responses on an axis between immunostimulatory and immunosuppressive. pDCs promote immune activation through an altered phenotype of persistent type I interferon secretion and weak antigen presentation capacity. Conversely, HIV-1 stimulates secretion of indolemine 2,3 dioxygenase (IDO) by pDCs resulting in Treg induction. An improved understanding of the roles and underlying mechanisms of DC dysfunction will be valuable to the development of therapeutics to enhance HIV-specific adaptive responses and to dampen immune activation.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23772620      PMCID: PMC5590719          DOI: 10.1111/imr.12082

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  196 in total

1.  IL-10 induces aberrant deletion of dendritic cells by natural killer cells in the context of HIV infection.

Authors:  Galit Alter; Daniel Kavanagh; Suzannah Rihn; Rutger Luteijn; David Brooks; Michael Oldstone; Jan van Lunzen; Marcus Altfeld
Journal:  J Clin Invest       Date:  2010-05-03       Impact factor: 14.808

2.  Dendritic cell targeted HIV gag protein vaccine provides help to a DNA vaccine including mobilization of protective CD8+ T cells.

Authors:  Godwin Nchinda; David Amadu; Christine Trumpfheller; Olga Mizenina; Klaus Uberla; Ralph M Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

3.  HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism.

Authors:  Olivier Manches; David Munn; Anahita Fallahi; Jeffrey Lifson; Laurence Chaperot; Joel Plumas; Nina Bhardwaj
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

4.  Activation of the noncanonical NF-κB pathway by HIV controls a dendritic cell immunoregulatory phenotype.

Authors:  Olivier Manches; Melissa Victoria Fernandez; Joel Plumas; Laurence Chaperot; Nina Bhardwaj
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-09       Impact factor: 11.205

Review 5.  Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance.

Authors:  Melissa Swiecki; Marco Colonna
Journal:  Immunol Rev       Date:  2010-03       Impact factor: 12.988

6.  Blockade of chronic type I interferon signaling to control persistent LCMV infection.

Authors:  Elizabeth B Wilson; Douglas H Yamada; Heidi Elsaesser; Jonathan Herskovitz; Jane Deng; Genhong Cheng; Bruce J Aronow; Christopher L Karp; David G Brooks
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

7.  Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response.

Authors:  Béatrice Jacquelin; Véronique Mayau; Brice Targat; Anne-Sophie Liovat; Désirée Kunkel; Gaël Petitjean; Marie-Agnès Dillies; Pierre Roques; Cécile Butor; Guido Silvestri; Luis D Giavedoni; Pierre Lebon; Françoise Barré-Sinoussi; Arndt Benecke; Michaela C Müller-Trutwin
Journal:  J Clin Invest       Date:  2009-12       Impact factor: 14.808

8.  Dysfunction and infection of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1.

Authors:  Heather Donaghy; Brian Gazzard; Frances Gotch; Steven Patterson
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

9.  Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy.

Authors:  Cara C Wilson; Mark J Newman; Brian D Livingston; Samantha MaWhinney; Jeri E Forster; Jim Scott; Robert T Schooley; Constance A Benson
Journal:  Clin Vaccine Immunol       Date:  2008-04-09

10.  Trex1 prevents cell-intrinsic initiation of autoimmunity.

Authors:  Daniel B Stetson; Joan S Ko; Thierry Heidmann; Ruslan Medzhitov
Journal:  Cell       Date:  2008-08-22       Impact factor: 41.582

View more
  47 in total

Review 1.  A pathogenic role of plasmacytoid dendritic cells in autoimmunity and chronic viral infection.

Authors:  Franck J Barrat; Lishan Su
Journal:  J Exp Med       Date:  2019-08-16       Impact factor: 14.307

2.  HIV-1 Tat Protein Activates both the MyD88 and TRIF Pathways To Induce Tumor Necrosis Factor Alpha and Interleukin-10 in Human Monocytes.

Authors:  Rémi Planès; Nawal Ben Haij; Kaoutar Leghmari; Manutea Serrero; Lbachir BenMohamed; Elmostafa Bahraoui
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

3.  Early SIV and HIV infection promotes the LILRB2/MHC-I inhibitory axis in cDCs.

Authors:  Lamine Alaoui; Gustavo Palomino; Sandy Zurawski; Gerard Zurawski; Sixtine Coindre; Nathalie Dereuddre-Bosquet; Camille Lecuroux; Cecile Goujard; Bruno Vaslin; Christine Bourgeois; Pierre Roques; Roger Le Grand; Olivier Lambotte; Benoit Favier
Journal:  Cell Mol Life Sci       Date:  2017-11-13       Impact factor: 9.261

Review 4.  Advances in dendritic cell immunotherapies for HIV-1 infection.

Authors:  Elizabeth Miller; Nina Bhardwaj
Journal:  Expert Opin Biol Ther       Date:  2014-08-21       Impact factor: 4.388

Review 5.  HIV infection: focus on the innate immune cells.

Authors:  Milena S Espíndola; Luana S Soares; Leonardo J Galvão-Lima; Fabiana A Zambuzi; Maira C Cacemiro; Verônica S Brauer; Fabiani G Frantz
Journal:  Immunol Res       Date:  2016-12       Impact factor: 2.829

Review 6.  Humoral immune responses to Streptococcus pneumoniae in the setting of HIV-1 infection.

Authors:  Lumin Zhang; Zihai Li; Zhuang Wan; Andrew Kilby; J Michael Kilby; Wei Jiang
Journal:  Vaccine       Date:  2015-06-30       Impact factor: 3.641

Review 7.  Trial watch: Dendritic cell-based anticancer therapy.

Authors:  Norma Bloy; Jonathan Pol; Fernando Aranda; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fučíková; Jérôme Galon; Eric Tartour; Radek Spisek; Madhav V Dhodapkar; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

Review 8.  Innate antiviral immune signaling, viral evasion and modulation by HIV-1.

Authors:  Arjun Rustagi; Michael Gale
Journal:  J Mol Biol       Date:  2013-12-08       Impact factor: 5.469

Review 9.  Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis.

Authors:  Yun Zhou; Ying Zhang; Jonathan P Moorman; Zhi Q Yao; Zhan S Jia
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

10.  Broadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes.

Authors:  Bin Su; Alexandre Lederle; Géraldine Laumond; Camille Ducloy; Sylvie Schmidt; Thomas Decoville; Christiane Moog
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.